18 May 2021 14:33
Immunodiagnostic Systems Holdings PLC
Director/PDMR Dealing
18 May 2021
Immunodiagnostic Systems Holdings PLC ("IDS") a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical and research markets, announces that it has granted the following options to persons discharging managerial responsibilities to acquire ordinary shares of 2p in the capital of the Company under the Company's Co-Investment Executive Option Scheme ("Scheme").
Employee | Position | Grant Date | Number of Options | Exercise Price |
Jaap Stuut | Chief Executive Officer | 17-May-21 | 7,500 | 1.95 |
Paul Martin | Chief Financial Officer | 17-May-21 | 6,300 | 2.75 |
17-May-21 | 6,000 | 1.95 | ||
Nicola Trewin | Group HR Director | 17-May-21 | 3,000 | 1.95 |
Soenke Weissenborn | Group Operations Director | 17-May-21 | 6,000 | 2.49 |
17-May-21 | 6,000 | 2.27 |
Under this Scheme, participants who purchase ordinary shares in the Company ("Co-Investment Shares") are entitled to three share options for each Co-Investment Share they purchase. The exercise price for the options is set at the price the participant paid for each Co-Investment Share.
The options are subject to the satisfaction of performance conditions and vest after a period of 3 years for the date of purchase of the Co-Investment Share. The options are exercisable over the period of 10 years from the date of grant.
In accordance with the operation of the Scheme in previous years, option awards were due to be granted on 31 March 2021 related to Co-Investment Shares purchased or rolled over in the financial year ended 31 March 2021, however this was not possible owing to the Company being in a close period.
All options granted at this time will be exercisable in full shortly prior to the scheme of arrangement to be implemented to effect the recommended cash offer for IDS by PerkinElmer (UK) Holdings Ltd (as referred to in the announcement made yesterday) becoming effective.
The below notifications, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, gives further detail of the number of options awarded.
For further information:
Immunodiagnostic Systems Holdings plc | Tel : +44 (0)191 519 0660 |
Paul Martin, Group Finance Director
| |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel | |
Victoria Erskine |
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||||||||||||||||
a. | Name | 1. Jaap Stuut 2. Paul Martin 3. Nicola Trewin 4. Soenke Weissenborn | ||||||||||||||||||||||||||
2. | Reason for the notification | |||||||||||||||||||||||||||
a. | Position/status | 1. Chief Executive Officer 2. Chief Financial Officer 3. Group HR Director 4. Group Operations Director
| ||||||||||||||||||||||||||
b. | Initial notification /Amendment | Initial | ||||||||||||||||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||||||||||
a. | Name | Immunodiagnostic Systems Holdings plc | ||||||||||||||||||||||||||
b. | LEI | 213800HZMYTD4NGF4L78 | ||||||||||||||||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||||||||||||||
a. | Description of the Financial instrument,
type of instrument
Identification code | Options over ordinary shares of 2p each in Immunodiagnostic Systems Holdings plc
Ordinary shares
GB00B01YZ052 | ||||||||||||||||||||||||||
b. | Nature of the transaction | Grant of Options
| ||||||||||||||||||||||||||
c. | Price(s) and volume(s) |
| ||||||||||||||||||||||||||
d. | Aggregated information · Aggregated volume · Price
|
| ||||||||||||||||||||||||||
e. | Date of the transaction | 17-May-21 | ||||||||||||||||||||||||||
f. | Place of the transaction | Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options | ||||||||||||||||||||||||||